Healthy Living Europe
SEE OTHER BRANDS

Keeping up with healthcare and wellness news from Europe

Healthy Living Europe: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthy Living Europe.

Press releases published on April 29, 2025

iTeos publie les résultats financiers de son premier trimestre 2025 et fait le point sur ses activités

iTeos publie les résultats financiers de son premier trimestre 2025 et fait le point sur ses activités

- Données de haut niveau provisoires issues de l’essai GALAXIES Lung-201, et plus de 240 patients attendus au deuxième trimestre 2025 - Données provisoires issues des essais GALAXIES H…

iTeos meldet Finanzergebnisse für das erste Quartal 2025 und gibt aktuelle Geschäftsinformationen bekannt

iTeos meldet Finanzergebnisse für das erste Quartal 2025 und gibt aktuelle Geschäftsinformationen bekannt

- Topline-Zwischenergebnisse von GALAXIES Lung-201 mit >240 Patienten im 2. Quartal 2025 erwartet - Zwischenergebnisse von GALAXIES H…

From Vietnam to Central Asia: GESO SYSTEMS Accelerates Its Globalization Strategy Once Again

From Vietnam to Central Asia: GESO SYSTEMS Accelerates Its Globalization Strategy Once Again

SHANGHAI, CHINA, April 29, 2025 /⁨EINPresswire.com⁩/ -- On April 22, 2025, the British GESO SYSTEMS was invited to participate in the Air Compressor Industry Product Exchange Meeting in Almaty, Kazakhstan, and discussed cooperation with industry …

Swiss Medica Advances Global Access to Stem Cell Therapy for Neurological and Chronic Conditions

Swiss Medica Advances Global Access to Stem Cell Therapy for Neurological and Chronic Conditions

Discover how a leading stem cell therapy clinic is making regenerative care more accessible for patients with chronic and neurological disorders. BELGRADE, SERBIA, April 29, 2025 /⁨EINPresswire.com⁩/ -- Swiss Medica, a leading stem cell clinic founded in …

Fortrea Releases Short Film ‘Transforming Lives’  to Showcase New Approaches, AI-Driven Advancements

Fortrea Releases Short Film ‘Transforming Lives’ to Showcase New Approaches, AI-Driven Advancements

Combining the Best People, Science and Technology Drives Clinical Trial Innovation DURHAM, NC, UNITED STATES, April 29, 2025 /⁨EINPresswire.com⁩/ -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), is being featured in the …

Cytek® Biosciences Brings Cutting-Edge Cell Analysis Solutions to CYTO and IMMUNOLOGY2025

Cytek® Biosciences Brings Cutting-Edge Cell Analysis Solutions to CYTO and IMMUNOLOGY2025

FREMONT, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Continuing its commitment to advancing cell analysis, Cytek Biosciences, Inc. (Nasdaq: CTKB) is showcasing its patented Full Spectrum Profiling™ (FSP®) technology at CYTO 2025 and American Association of …

Nuo Therapeutics Announces Exclusive Private Label Distribution Agreement with Smith+Nephew

Nuo Therapeutics Announces Exclusive Private Label Distribution Agreement with Smith+Nephew

HOUSTON, April 29, 2025 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo”), a commercial stage medical device company pioneering leading-edge biodynamic therapies by focusing on emerging opportunities in the evolving healthcare landscape, …

Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting

Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting

Phase 1a dose-escalation study data update: treatment with NXP900 resulted in exposure levels leading to robust pharmacodynamic responses across a range of tolerated doses; NXP900 has an acceptable safety profile, dose limiting toxicity dose level has not …

Certara to Participate in Upcoming Investor Conferences

Certara to Participate in Upcoming Investor Conferences

RADNOR, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences: BofA Securities 2025 …

Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement

Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement

-- Nasdaq Compliance Follows ADS Ratio Change to Secure Company’s Public Listing -- -- Amarin Remains Focused on Maximizing the Global Value of VASCEPA/VAZKEPA – DUBLIN and BRIDGEWATER, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc ( …

CooperCompanies Announces Release Date for Second Quarter 2025

CooperCompanies Announces Release Date for Second Quarter 2025

 SAN RAMON, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today it will report second quarter 2025 financial results on Thursday, May 29, 2025, at 4:15 PM ET. Following the release, …

The Ensign Group Reports First Quarter 2025 Results; Raises Annual Earnings and Revenue Guidance

The Ensign Group Reports First Quarter 2025 Results; Raises Annual Earnings and Revenue Guidance

SAN JUAN CAPISTRANO, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign(TM) group of companies, which provide post-acute healthcare services and invest in the long-term healthcare industry, …

Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis

Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis

Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis The Phase 3 ABTECT trials (Studies 105 and 106) evaluating obefazimod in patients with moderately to severely active …

Senseonics Holdings, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call for May 8, 2025 at 4:30 P.M. Eastern Time

Senseonics Holdings, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call for May 8, 2025 at 4:30 P.M. Eastern Time

GERMANTOWN, Md., April 29, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people …

Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting

Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting

ERAS-0015 and ERAS-4001 showed robust anti-tumor activity as monotherapy and combination therapy First-in-class examples of direct SHOC2 binders and modulators of SMP complex assembly identified with potential to block oncogenic RAS/MAPK pathway signaling …

PROCEPT BioRobotics® to Attend Four Upcoming Investor Conferences in May & June

PROCEPT BioRobotics® to Attend Four Upcoming Investor Conferences in May & June

SAN JOSE, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today that members of …

BridgeBio Reports First Quarter 2025 Financial Results and Business Updates

BridgeBio Reports First Quarter 2025 Financial Results and Business Updates

- $36.7 million in first full quarter of U.S. Attruby™ net product revenue and as of April 25, 2025, 2,072 unique patient prescriptions written by 756 unique prescribers - Observational run-in study for hypochondroplasia Phase 2 trial fully enrolled …

BeautyHealth to Report First Quarter 2025 Financial Results on May 8, 2025

BeautyHealth to Report First Quarter 2025 Financial Results on May 8, 2025

LONG BEACH, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- The Beauty Health Company (NASDAQ:SKIN), home to flagship brand Hydrafacial™, today announced it will report first quarter 2025 financial results after market close on Thursday, May 8, 2025. The …

Artios Pharma Reports Differentiated Clinical Activity in STELLA Phase 1/2a Study for Lead Program ART0380 at the American Association for Cancer Research (AACR) Annual Meeting 2025

Artios Pharma Reports Differentiated Clinical Activity in STELLA Phase 1/2a Study for Lead Program ART0380 at the American Association for Cancer Research (AACR) Annual Meeting 2025

ART0380 in combination with low-dose irinotecan demonstrated a 50% confirmed overall response rate (cORR) in patients with Ataxia-Telangiectasia Mutated (ATM)-negative1 solid tumors at the recommended Phase 2 dose (RP2D) 37% cORR observed in patients with …

Nouscom Presents Positive Final Results from Completed Phase Ib/II Study of Neoantigen Immunotherapy NOUS-209 at AACR 2025, Demonstrating a Highly Potent and Durable Immune Response in Lynch Syndrome Carriers

Nouscom Presents Positive Final Results from Completed Phase Ib/II Study of Neoantigen Immunotherapy NOUS-209 at AACR 2025, Demonstrating a Highly Potent and Durable Immune Response in Lynch Syndrome Carriers

Lynch Syndrome (LS) is a common hereditary condition that significantly increases the lifetime risk of cancer, especially colorectal and endometrial, to as high as 80% NOUS-209 is an off-the-shelf immunotherapy designed to harness the power of the immune …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service